Liquidity and going-concern risk
Negative operating cash flow, an accumulated deficit, and reliance on debt or capital markets create a risk that funding may not be available when needed.
- Scope
- Company-wide operations
- Materiality
- high
CV Sciences, Inc.
CV Sciences, Inc. is a U.S.-based consumer products and development company focused on hemp-derived CBD products and related herbal supplements, with an additional drug development program centered on CBD-based therapeutics. The company sells branded consumer products and also appears to participate in contract manufacturing activity, while continuing to evaluate acquisitions to broaden its platform. Its operations are shaped by a fragmented regulatory environment, intense competition from licensed and illicit market participants, and ongoing liquidity constraints. CV Sciences has also been reducing costs and delaying discretionary spending to preserve capital while it seeks to stabilize revenue and fund growth initiatives.
−2,0 %
49,0 %
−6,9 %
−12,2 %
1.03
0.21
| % | |
|---|---|
| CBD consumer products | 70% Branded hemp-derived CBD products sold to consumers through retail and other channels. |
| Herbal supplements | 15% Supplement products that compete in adjacent wellness and nutraceutical categories. |
| Contract manufacturing | 10% Third-party manufacturing revenue tied to producing products for other customers. |
| CBD therapeutics development | 5% Early-stage drug development work focused on CBD-based novel therapeutics. |
CV Sciences sells primarily to consumers seeking hemp-derived CBD and wellness products, with demand driven by brand...
- CBD wellness consumersprimary
Buy hemp-derived CBD products for wellness, recovery, or general health use and choose based on brand, quality, and availability.
- Herbal supplement consumerssecondary
Buy adjacent supplement products that overlap with the company’s wellness positioning and broaden the basket size.
- Channel and retail partnerssecondary
Purchase products for resale because branded CBD and supplement items can generate consumer demand through distribution networks.
- Contract manufacturing customersemerging
Use the company for third-party production when they need manufacturing capacity and product formulation support.
CV Sciences is headquartered in the United States and appears to generate most of its business there, with operations...
- •United States is the core market for sales and regulatory exposure
- •San Diego, California is a primary office and operating location
- •Grand Junction, Colorado supports manufacturing or operational activity
- •Warsaw, Poland indicates an international facility footprint
- •State-by-state CBD regulation affects where products can be sold
- •No country-level revenue disclosure was provided in the excerpts
CV Sciences is focused on rebuilding and diversifying its consumer products platform while preserving liquidity...
01
New product innovation and launchesshort-term
New products are a key lever for revenue growth in a market where customers can easily switch to competitors.
02
Cost reduction and liquidity preservationshort-term
The company has negative operating cash flow and a going-concern risk, so preserving cash is essential to continue operations.
03
Platform diversification through acquisitionsmedium-term
Acquisitions could broaden the product mix and reduce dependence on a single CBD category.
04
CBD therapeutics developmentlong-term
The drug development program could create a higher-value pipeline if capital becomes available.
CV Sciences faces substantial business risk from a fragmented and weakly regulated CBD market, where licensed and...
Regulatory uncertainty in CBD markets
The company operates in a market with a lack of a clear regulatory framework and patchwork state rules, which can restrict sales and increase compliance costs.
- Scope
- CBD consumer products and herbal supplements
- Materiality
- high
Manufacturing and supply disruptions
Out-of-stock issues and manufacturing constraints can reduce sales, hurt customer retention, and delay revenue recognition timing.
- Scope
- Key products and near-term sales
- Materiality
- high
Competitive pressure from low-barrier entrants
Licensed and illicit operators can offer substitute products, pressuring pricing, margins, and market share.
- Scope
- CBD consumer products
- Materiality
- high
Execution risk on acquisitions and strategic changes
The company is pursuing acquisitions and strategic alternatives while also cutting costs, which can distract management and create integration risk.
- Scope
- Growth strategy
- Materiality
- medium
Going-concern disclosure
Can affect asset valuation, liability classification, and investor assessment of solvency
Debt discount and issuance cost amortization
Impacts net loss and financing cost analysis
Contingent liability estimate reversal
Can create non-recurring gains or losses
Revenue and inventory timing
Affects revenue comparability and gross profit
cbdMD, Inc.
YCBD · Perfumes, Cosmetics & Other Toilet Preparations
Charlie's Holdings, Inc.
CHUC · Medicinal Chemicals & Botanical Products
Bespoke Extracts, Inc.
BSPK · Pharmaceutical Preparations
Cannabis Bioscience International Holdings, Inc.
CBIH · Services-Commercial Physical & Biological Research
CFN Enterprises Inc.
CNFN · Services-Business Services, NEC
Cannaisseur Group Inc.
TCRG · Medicinal Chemicals & Botanical Products
: 11/08/2026